Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency | Zendy

Stefan D. Anker | Zendy; Josep Comín Colet | Zendy; Gerasimos Filippatos | Zendy; Ronnie Willenheimer | Zendy; Kenneth Dickstein | Zendy; Helmut Drexler | Zendy; Thomas F. Lüscher | Zendy; B. Ya. Bart | Zendy; Waldemar Banasiak | Zendy; Joaniegowska | Zendy; BridgetAnne Kirwan | Zendy; Claudio Mori | Zendy; B. Rothe | Zendy; Stuart J. Pocock | Zendy; Philip A. PooleWilson | Zendy; Piotr Ponikowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

Author(s) -

Stefan D. Anker,

Josep Comín Colet,

Gerasimos Filippatos,

Ronnie Willenheimer,

Kenneth Dickstein,

Helmut Drexler,

Thomas F. Lüscher,

B. Ya. Bart,

Waldemar Banasiak,

Joaniegowska,

BridgetAnne Kirwan,

Claudio Mori,

B. Rothe,

Stuart J. Pocock,

Philip A. PooleWilson,

Piotr Ponikowski

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0908355

Subject(s) - medicine , heart failure , iron deficiency , anemia , iron deficiency anemia , ejection fraction , gastroenterology

Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research